JP2011518817A - ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類 - Google Patents

ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類 Download PDF

Info

Publication number
JP2011518817A
JP2011518817A JP2011505589A JP2011505589A JP2011518817A JP 2011518817 A JP2011518817 A JP 2011518817A JP 2011505589 A JP2011505589 A JP 2011505589A JP 2011505589 A JP2011505589 A JP 2011505589A JP 2011518817 A JP2011518817 A JP 2011518817A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
group
optionally substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518817A5 (enExample
Inventor
モファット，デイヴィッド，フェスタス，チャールズ
デイビス，スティーブン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0807642A external-priority patent/GB0807642D0/en
Priority claimed from GB0815550A external-priority patent/GB0815550D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of JP2011518817A publication Critical patent/JP2011518817A/ja
Publication of JP2011518817A5 publication Critical patent/JP2011518817A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2011505589A 2008-04-26 2009-04-23 ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類 Withdrawn JP2011518817A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0807642.4 2008-04-26
GB0807642A GB0807642D0 (en) 2008-04-26 2008-04-26 IKK- serine-threonine protein kinase inhibitors
GB0815550.9 2008-08-27
GB0815550A GB0815550D0 (en) 2008-08-27 2008-08-27 IKK-beta serine-threonine protein kinase inhibitors
PCT/GB2009/001051 WO2009130475A1 (en) 2008-04-26 2009-04-23 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2011518817A true JP2011518817A (ja) 2011-06-30
JP2011518817A5 JP2011518817A5 (enExample) 2012-06-07

Family

ID=40786701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505589A Withdrawn JP2011518817A (ja) 2008-04-26 2009-04-23 ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類

Country Status (13)

Country Link
US (1) US20110046210A1 (enExample)
EP (1) EP2285797A1 (enExample)
JP (1) JP2011518817A (enExample)
KR (1) KR20110020784A (enExample)
CN (1) CN102036980A (enExample)
AU (1) AU2009239772A1 (enExample)
BR (1) BRPI0911480A2 (enExample)
CA (1) CA2722660A1 (enExample)
EA (1) EA201001708A1 (enExample)
IL (1) IL208654A0 (enExample)
MX (1) MX2010011643A (enExample)
WO (1) WO2009130475A1 (enExample)
ZA (1) ZA201008027B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012176930A (ja) * 2010-10-07 2012-09-13 Santen Pharmaceut Co Ltd ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
DK3222616T3 (da) 2012-10-17 2019-08-19 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorbenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorphenyl}ethyl]-L-alanin og terbutylester deraf
EA028858B9 (ru) 2013-02-06 2018-06-29 Байер Кропсайенс Акциенгезельшафт Галогензамещенные производные пиразола в качестве средств борьбы с вредителями
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
ATE522516T1 (de) * 2006-11-01 2011-09-15 Chroma Therapeutics Ltd Inhibitoren der ikk-beta-serin-threonin- proteinkinase
WO2008053185A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE

Also Published As

Publication number Publication date
BRPI0911480A2 (pt) 2018-04-03
IL208654A0 (en) 2010-12-30
MX2010011643A (es) 2010-11-30
US20110046210A1 (en) 2011-02-24
KR20110020784A (ko) 2011-03-03
AU2009239772A1 (en) 2009-10-29
ZA201008027B (en) 2011-07-27
CA2722660A1 (en) 2009-10-29
EP2285797A1 (en) 2011-02-23
EA201001708A1 (ru) 2011-06-30
CN102036980A (zh) 2011-04-27
WO2009130475A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
EP2078007B1 (en) Ikk-beta serine-threonine protein kinase inhibitors
EP2086956B1 (en) Inhibitors of ikk- beta serine-threonine protein kinase
JP5043120B2 (ja) ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
JP5340918B2 (ja) ｐ３８ＭＡＰキナーゼ阻害剤
WO2008050078A1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
JP2011513288A (ja) ｐ３８ＭＡＰキナーゼ阻害剤
JP2011518817A (ja) ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類
KR20110021799A (ko) Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제의 억제제
WO2008053158A1 (en) Inhibitors of p38 mitogen-activated protein kinase
JP2012524767A (ja) Ｉｋｋ−ｂセリン・スレオニンプロテインキナーゼのチオフェン阻害剤
CN101541779A (zh) IKK-β丝氨酸-苏氨酸蛋白激酶抑制剂
WO2009141575A1 (en) Inhibitors of plk
CN101437799A (zh) p38MAP激酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120419

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120911